Literature DB >> 19209141

Appropriate thromboprophylaxis in hospitalized cancer patients.

Alpesh Amin1, Stephen Stemkowski, Jay Lin, Guiping Yang.   

Abstract

BACKGROUND: Cancer is associated with an increased risk of venous thromboembolism (VTE) in hospitalized patients. Despite availability of evidence-based guidelines recommending thromboprophylaxis in cancer patients, many cancer patients do not receive appropriate thromboprophylaxis. This study provides a large, real-world analysis of the rates of thromboprophylaxis use in hospitalized cancer patient discharges.
METHODS: Hospital discharge information from the Premier Perspective inpatient database from January 2002-September 2005 was used. Included discharges had a principal diagnosis of cancer, were aged 40 years or older, had a length of hospital stay of 6 days or more, and had no contraindications for anticoagulation. The rate of appropriate VTE prophylaxis was determined according to the 7th American College of Chest Physicians guidelines, taking into account mechanical compression and chemoprophylaxis, dosage of anticoagulant, and duration of therapy.
RESULTS: A total of 72,337 cancer discharges with an indication for thromboprophylaxis were identified (30,124 surgical, 42,213 nonsurgical). The overall rate of any level of VTE prophylaxis was 53.6%; however, the rate of appropriate thromboprophylaxis (according to the 7th ACCP guidelines) was 27.0% (27.0% surgical, 27.1% nonsurgical). The most common reason for inappropriate prophylaxis (46.0% of all discharges) was no prophylaxis received, despite having no contra-indication to anticoagulation.
CONCLUSIONS: This study highlights that despite the presence of evidence-based guidelines, appropriate thromboprophylaxis is severely underused in all types of at-risk cancer patients. Greater efforts are needed to improve the implementation of guidelines, and to ensure that more cancer patients receive appropriate thromboprophylaxis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19209141

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  6 in total

1.  The AVAIL ME study: a multinational survey of VTE risk and prophylaxis.

Authors:  Ali T Taher; Joseph Aoun; Pascale Salameh
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

Review 2.  Can heparins stimulate bone cancer stem cells and interfere with tumorigenesis?

Authors:  M Reza Sadaie
Journal:  Ther Adv Drug Saf       Date:  2011-12

3.  Pattern of Venous Thrombosis in Cancer Patients: Frequency and Survival Effect; Single Center Experience.

Authors:  Amrallah A Mohammed; Abdullah S Al-Zahrani; Mian U Farooq; Hafez M Ghanem; Lobna A Abdelaziz; Hani M El-Khatib
Journal:  Indian J Hematol Blood Transfus       Date:  2015-01-23       Impact factor: 0.900

4.  Deep learning detects and visualizes bleeding events in electronic health records.

Authors:  Jannik S Pedersen; Martin S Laursen; Thiusius Rajeeth Savarimuthu; Rasmus Søgaard Hansen; Anne Bryde Alnor; Kristian Voss Bjerre; Ina Mathilde Kjær; Charlotte Gils; Anne-Sofie Faarvang Thorsen; Eline Sandvig Andersen; Cathrine Brødsgaard Nielsen; Lou-Ann Christensen Andersen; Søren Andreas Just; Pernille Just Vinholt
Journal:  Res Pract Thromb Haemost       Date:  2021-05-05

5.  Venous thromboembolism prophylaxis in patients undergoing abdominal and pelvic cancer surgery: adherence and compliance to ACCP guidelines in DIONYS registry.

Authors:  Melkart Basile; Maroon Tohmeh; Negib Geahchan
Journal:  Springerplus       Date:  2016-09-13

6.  Appropriateness of Pharmacologic Prophylaxis against Deep Vein Thrombosis in Medical Wards of an Ethiopian Referral Hospital.

Authors:  Mohammed Biset Ayalew; Boressa Adugna Horsa; Meseret Tilahun Zeleke
Journal:  Int J Vasc Med       Date:  2018-07-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.